Betaxolol hydrochloride

Therapeutic Function Adrenergic blocking agent for cardiovascular problems 

Chemical Neme 1 -[4-[2-(Cyclopropylmethoxy)ethyl]phenoxy ]-3-[(1 -methylethyl)amino] 2-propanol hydrochloride 

---

Betaxolol hydrochloride is a lipophilic, cardioselective -adrenoceptor blocker having no ISA and Httie membrane-stabilizing activity. The dmg is as equieffective and equipotent as atenolol. It is well absorbed from the GI tract, but does not undergo extensive first-pass metaboHsm in the Hver. Its elimination half-Hfe is 15—20 h. It is metabolized in the Hver ( 84%) to two principal inactive metaboHtes and one minor active metaboHte. About 16% of the dmg is excreted unchanged urine. Excretion of the dmg is unchanged in patients having renal or Hver impairment (43). 

Hemodialysis - Give 25 or 50 mg after each dialysis. BETAXOLOL HYDROCHLORIDE ... 

BETAXOLOL HYDROCHLORIDE Instill 1 to 2 drops twice daily. 

Suspensions If the drug is not sufficiently soluble, it can be formulated as a suspension. A suspension may also be desired to improve stability, bioavailability, or efficacy. The major topical ophthalmic suspensions include but are not limited to steroid anti-inflammatory agents and lOP-lowering agents prednisolone acetate, dexamethasone, fluorometholone, nepafenac, brinzolamide, betaxolol hydrochloride, and rimexolone. Water-soluble salts of prednisolone phosphate and dexamethasone phosphate are available however, they have a lower steroid potency and are poorly absorbed. 

Betaxolol hydrochloride is a cardioselective B-adrenergic blocker, reportedly devoid of intrinsic sympathomimetic emd membrame stabilizing properties. Its long duration of action permits once-daily dosing in mild to moderate hypertension. It is also being evaluated in glaucoma. 

Plager DA, Whitson JT, Netland PA, Vijaya L, Sathyan P, Sood D, Krishnadas SR, Robin AL, Gross RD, Scheib SA, Scott H, Dickerson JE. BETOPTIC S Pediatric Study Group. Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma a randomized clinical trial J AAPOS 2009 13(4) 384-90. 

Comparative studies In 105 children who were treated with either betaxolol hydrochloride ophthalmic suspension 0.25% or timolol maleate ophthalmic gel-forming solution 0.25% and 0.5% after randomization, adverse events were mostly non-seri-ous and mild to moderate in intensity [26 ]. No patient stopped treatment because of adverse events, which were hyperemia of the eye, discomfort, irritation of the eye, discharge from the eye, lid margin crusting, pruritus of the eye, a sticky sensation, bradycardia, and hypotension. 

---